Budesonide — A New Steroid for Intranasal Use

Abstract
Patients (29) with seasonal rhinitis completed a doube-blind study comparing budesonide nasal spray 200 .mu.g b.i.d. [twice daily] with placebo. The patients were randomly assigned ito 2 parallel groups. Symptoms were assessed over a treatment period of 3 wk. There were statistically significant differences in favor of budesonide on all measurements. Side effects were mild and the incidence was low.